{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:07:53Z","timestamp":1788908873530,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04434-1","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T08:15:49Z","timestamp":1768378549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PSMA\/PET-guided stereotactic radiosurgery treatment for intracranial metastases from prostate cancer"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9746-7931","authenticated-orcid":false,"given":"Victor","family":"Goulenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-9802","authenticated-orcid":false,"given":"Fatemeh","family":"Fekrmandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1517-9707","authenticated-orcid":false,"given":"Venkatesh Shankar","family":"Madhugiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil D.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Lipinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Fabiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth V.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurkamal","family":"Chatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurshid A.","family":"Guru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Kuettel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0309-8130","authenticated-orcid":false,"given":"Robert A.","family":"Fenstermaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9388-9876","authenticated-orcid":false,"given":"Robert J.","family":"Plunkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6615-4235","authenticated-orcid":false,"given":"Dheerendra","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"4434_CR1","doi-asserted-by":"publisher","first-page":"111711","DOI":"10.1016\/j.ejrad.2024.111711","volume":"180","author":"D Yadav","year":"2024","unstructured":"Yadav D, Dutruel SP, O\u2019Dwyer E, Ricaurte-Fajardo A, Upadhyay R, Palmer JD, Pannullo SC, Tagawa ST, Knisely JPS, Brandmaier A, Osborne JR, Ivanidze J. PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer. Eur J Radiol. 2024;180:111711. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111711.","journal-title":"Eur J Radiol"},{"key":"4434_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Perez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ, Investigators V. Lutetium-177-PSMA-617 for metastatic Castration-Resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"4434_CR3","doi-asserted-by":"publisher","unstructured":"Kinikoglu O, Oven BB, Celik S, Alan Selcuk N, Beydagi G, Akcay K, Kabasakal L. Investigating combination therapy: the role of Lutetium-177 PSMA-617 radioligand therapy and androgen receptor pathway inhibitors in metastatic Castration-Resistant prostate cancer. J Clin Med. 2024;13. https:\/\/doi.org\/10.3390\/jcm13164585.","DOI":"10.3390\/jcm13164585"},{"key":"4434_CR4","doi-asserted-by":"publisher","unstructured":"Pastorello E, Nicosia L, Cuccia F, Olivari L, Fiorini M, Giaj Levra N, Mazzola R, Ricchetti F, Rigo M, Ravelli P, D\u2019Alessandro S, Salgarello M, Ruggieri R, Alongi F. PSMA-PET\/CT-Based stereotactic body radiotherapy (SBRT) in the treatment of uncomplicated Non-Spinal bone oligometastases from prostate cancer. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15102800.","DOI":"10.3390\/cancers15102800"},{"key":"4434_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10585-022-10157-8","volume":"39","author":"R Mazzola","year":"2022","unstructured":"Mazzola R, Cuccia F, Pastorello E, Salgarello M, Francolini G, Livi L, Triggiani L, Magrini SM, Ingrosso G, Aristei C, Franzese C, Scorsetti M, Alongi F. PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study. Clin Exp Metastasis. 2022;39:443\u20138. https:\/\/doi.org\/10.1007\/s10585-022-10157-8.","journal-title":"Clin Exp Metastasis"},{"key":"4434_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cncr.11522","volume":"98","author":"IW Tremont-Lukats","year":"2003","unstructured":"Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: the M. D. Anderson cancer center experience. Cancer. 2003;98:363\u20138. https:\/\/doi.org\/10.1002\/cncr.11522.","journal-title":"Cancer"},{"key":"4434_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/RLU.0000000000000709","volume":"40","author":"PS Chakraborty","year":"2015","unstructured":"Chakraborty PS, Kumar R, Tripathi M, Das CJ, Bal C. Detection of brain metastasis with 68Ga-labeled PSMA ligand PET\/CT: a novel Radiotracer for imaging of prostate carcinoma. Clin Nucl Med. 2015;40:328\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000000709.","journal-title":"Clin Nucl Med"},{"key":"4434_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11060-023-04355-x","volume":"163","author":"LA McLaughlin","year":"2023","unstructured":"McLaughlin LA, Yildirim O, Rosenblum MK, Imber BS, Haseltine JM, Zelefsky MJ, Schoder H, Morris MJ, Rafelson WM, Krebs S, Moss NS. Identification of incidental brain tumors in prostate cancer patients via PSMA PET\/CT. J Neurooncol. 2023;163:455\u201362. https:\/\/doi.org\/10.1007\/s11060-023-04355-x.","journal-title":"J Neurooncol"},{"key":"4434_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4103\/ijnm.ijnm_100_21","volume":"37","author":"HS Nellaiappan","year":"2022","unstructured":"Nellaiappan HS, Rajaraman V, Halanaik D, Ananthakrrishnan R. Incidental detection of asymptomatic brain metastases due to carcinoma prostate in Ga-68 PSMA HBED-CC positron emission Tomography-Computed tomography: reiterating its superiority in assessing disease status. Indian J Nucl Med. 2022;37:99\u2013100. https:\/\/doi.org\/10.4103\/ijnm.ijnm_100_21.","journal-title":"Indian J Nucl Med"},{"key":"4434_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13550-020-00696-0","volume":"10","author":"MI Ross","year":"2020","unstructured":"Ross MI, Bird N, Mendichovszky IA, Rimmer YL. Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET\/CT. EJNMMI Res. 2020;10:108. https:\/\/doi.org\/10.1186\/s13550-020-00696-0.","journal-title":"EJNMMI Res"},{"key":"4434_CR11","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1097\/RLU.0000000000002548","volume":"44","author":"C Yin","year":"2019","unstructured":"Yin C, Ho B, Chan L, Emmett L. Asymptomatic prostate cancer brain metastases on 68Ga-PSMA PET\/CT. Clin Nucl Med. 2019;44:e382\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000002548.","journal-title":"Clin Nucl Med"},{"key":"4434_CR12","doi-asserted-by":"publisher","unstructured":"Mondia MWL, Batchala PP, Dreicer R, Devitt ME, McCord MR, Mut M, Sheehan JP, Schiff D, Fadul CE. Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET\/CT and MRI: A Case Series and Literature Review. Prostate. 2025. https:\/\/doi.org\/10.1002\/pros.24890","DOI":"10.1002\/pros.24890"},{"key":"4434_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11060-012-0994-1","volume":"111","author":"O Caffo","year":"2013","unstructured":"Caffo O, Veccia A, Fellin G, Mussari S, Russo L, Tomio L, Galligioni E. Frequency of brain metastases from prostate cancer: an 18-year single-institution experience. J Neurooncol. 2013;111:163\u20137. https:\/\/doi.org\/10.1007\/s11060-012-0994-1.","journal-title":"J Neurooncol"},{"key":"4434_CR14","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1001\/jamaoncol.2022.1928","volume":"8","author":"NS Moss","year":"2022","unstructured":"Moss NS, Beal K, Tabar V. Brain Metastasis-A distinct oncologic disease best served by an integrated multidisciplinary team approach. JAMA Oncol. 2022;8:1252\u20134. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1928.","journal-title":"JAMA Oncol"},{"key":"4434_CR15","doi-asserted-by":"publisher","first-page":"109199","DOI":"10.1016\/j.ejrad.2020.109199","volume":"130","author":"E Akgun","year":"2020","unstructured":"Akgun E, Akgun MY, Selcuk HH, Uzan M, Sayman HB. (68)Ga PSMA PET\/MR in the differentiation of low and high grade gliomas: is (68)Ga PSMA PET\/MRI useful to detect brain gliomas? Eur J Radiol. 2020;130:109199. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109199.","journal-title":"Eur J Radiol"},{"key":"4434_CR16","doi-asserted-by":"publisher","unstructured":"Brighi C, Puttick S, Woods A, Keall P, Tooney PA, Waddington DEJ, Sproule V, Rose S, Fay M. Comparison between [(68)Ga]Ga-PSMA-617 and [(18)F]FET PET as imaging biomarkers in adult recurrent glioblastoma. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms242216208.","DOI":"10.3390\/ijms242216208"},{"key":"4434_CR17","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1097\/RLU.0000000000001451","volume":"42","author":"A Sasikumar","year":"2017","unstructured":"Sasikumar A, Joy A, Pillai MR, Nanabala R, Anees KM, Jayaprakash PG, Madhavan J, Nair S. Diagnostic value of 68Ga PSMA-11 PET\/CT imaging of brain Tumors-Preliminary analysis. Clin Nucl Med. 2017;42:e41\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000001451.","journal-title":"Clin Nucl Med"},{"key":"4434_CR18","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1097\/RLU.0000000000003629","volume":"46","author":"N Filizoglu","year":"2021","unstructured":"Filizoglu N, Oksuzoglu K, Ozguven S. Distinguishing meningioma from metastasis of prostate cancer on 68Ga-PSMA PET\/CT. Clin Nucl Med. 2021;46:e553\u20135. https:\/\/doi.org\/10.1097\/RLU.0000000000003629.","journal-title":"Clin Nucl Med"},{"key":"4434_CR19","doi-asserted-by":"publisher","first-page":"101616","DOI":"10.1016\/j.tranon.2023.101616","volume":"28","author":"Y Pei","year":"2023","unstructured":"Pei Y, Liu C, Feng M, Li L, Zhou C, Chen L, Hu X, Song S, Cao Y, Gao Y. The clinical application of (68)Ga-PSMA PET\/CT and regulating mechanism of PSMA expression in patients with brain metastases of lung cancer. Transl Oncol. 2023;28:101616. https:\/\/doi.org\/10.1016\/j.tranon.2023.101616.","journal-title":"Transl Oncol"},{"key":"4434_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10585-018-9878-x","volume":"34","author":"M Kasoha","year":"2017","unstructured":"Kasoha M, Unger C, Solomayer EF, Bohle RM, Zaharia C, Khreich F, Wagenpfeil S, Juhasz-Boss I. Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases. Clin Exp Metastasis. 2017;34:479\u201390. https:\/\/doi.org\/10.1007\/s10585-018-9878-x.","journal-title":"Clin Exp Metastasis"},{"key":"4434_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40644-020-00300-7","volume":"20","author":"F de Galiza Barbosa","year":"2020","unstructured":"de Galiza Barbosa F, Queiroz MA, Nunes RF, Costa LB, Zaniboni EC, Marin JFG, Cerri GG, Buchpiguel CA. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20:23. https:\/\/doi.org\/10.1186\/s40644-020-00300-7.","journal-title":"Cancer Imaging"},{"key":"4434_CR22","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1111\/jcmm.15350","volume":"24","author":"J Tanjore Ramanathan","year":"2020","unstructured":"Tanjore Ramanathan J, Lehtipuro S, Sihto H, Tovari J, Reiniger L, Teglasi V, Moldvay J, Nykter M, Haapasalo H, Le Joncour V, Laakkonen P. Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain. J Cell Mol Med. 2020;24:6916\u201327. https:\/\/doi.org\/10.1111\/jcmm.15350.","journal-title":"J Cell Mol Med"},{"key":"4434_CR23","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.radcr.2024.02.110","volume":"19","author":"A Al-Zubaidi","year":"2024","unstructured":"Al-Zubaidi A, Bezold S, Bhargava P, Villanueva-Meyer J. Prostate cancer brain metastases: monitoring response to treatment with PSMA PET\/CT. Radiol Case Rep. 2024;19:2367\u201370. https:\/\/doi.org\/10.1016\/j.radcr.2024.02.110.","journal-title":"Radiol Case Rep"},{"key":"4434_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/RLU.0000000000003820","volume":"46","author":"N Filizoglu","year":"2021","unstructured":"Filizoglu N, Cetin IA, Kissa TN, Niftaliyeva K, Ones T. 68Ga-PSMA PET\/CT to distinguish brain metastasis of renal cell carcinoma from radiation necrosis after stereotactic radiosurgery. Clin Nucl Med. 2021;46:913\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000003820.","journal-title":"Clin Nucl Med"},{"key":"4434_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11060-024-04697-0","volume":"168","author":"V Goulenko","year":"2024","unstructured":"Goulenko V, Madhugiri VS, Bregy A, Recker M, Lipinski L, Fabiano A, Fenstermaker R, Plunkett R, Abad A, Belal A, Alberico R, Qiu J, Prasad D. Histopathological correlation of brain tumor recurrence vs. radiation effect post-radiosurgery as detected by MRI contrast clearance analysis: a validation study. J Neurooncol. 2024;168:547\u201353. https:\/\/doi.org\/10.1007\/s11060-024-04697-0.","journal-title":"J Neurooncol"},{"key":"4434_CR26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269175","author":"BS Imber","year":"2025","unstructured":"Imber BS, Yu KKH, Abida W, Pike LRG, Grkovski M, Kaley TJ, Morris MJ, Bodei L, Nosov A, Dunphy MPS, Schoder H, Fox JJ, Rosenblum M, Bale T, Krebs S. Symptomatic Prostate-Specific membrane antigen PET-Positive radionecrosis after multimodality brain Metastasis-Directed treatment including [(177)Lu]Lu-PSMA-617. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.124.269175.","journal-title":"J Nucl Med"},{"key":"4434_CR27","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/MNM.0000000000001361","volume":"42","author":"B Singh","year":"2021","unstructured":"Singh B, Sharma S, Bansal P, Hooda M, Singh H, Parihar AS, Kumar A, Watts A, Mohan R, Singh SK. Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET\/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality. Nucl Med Commun. 2021;42:482\u20139. https:\/\/doi.org\/10.1097\/MNM.0000000000001361.","journal-title":"Nucl Med Commun"},{"key":"4434_CR28","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/RLU.0000000000003410","volume":"46","author":"B Fallahi","year":"2021","unstructured":"Fallahi B, Khademi N, Karamzade-Ziarati N, Fard-Esfahani A, Emami-Ardekani A, Farzanefar S, Eftekhari M, Beiki D. 99mTc-PSMA SPECT\/CT versus 68Ga-PSMA PET\/CT in the evaluation of metastatic prostate cancer. Clin Nucl Med. 2021;46:e68\u201374. https:\/\/doi.org\/10.1097\/RLU.0000000000003410.","journal-title":"Clin Nucl Med"},{"key":"4434_CR29","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/RLU.0000000000003702","volume":"46","author":"J Kabunda","year":"2021","unstructured":"Kabunda J, Gabela L, Kalinda C, Aldous C, Pillay V, Nyakale N. Comparing 99mTc-PSMA to 99mTc-MDP in prostate cancer staging of the skeletal system. Clin Nucl Med. 2021;46:562\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000003702.","journal-title":"Clin Nucl Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04434-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:43:54Z","timestamp":1770723834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04434-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4434"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04434-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This observational study was approved by the Roswell Park Comprehensive Cancer Center\u2019s Institutional Review Board under the identification number 2786. The study protocol was carried out in accordance with the ethical standards established in the 1964 Declaration of Helsinki and its subsequent amendments. All necessary written informed consents were obtained. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved the final version of this manuscript and consent to its publication in Discover Oncology \u2013 Springer Nature. The work is original, has not been published previously, and is not under consideration for publication elsewhere. All applicable ethical standards were followed, and informed consent was obtained when required. Patient data have been de-identified to protect privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author Dheerendra Prasad works as a consultant for Elekta, AB (Stockholm, Sweden). The other authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}